AcelRx Pharmaceuticals Inc(NASDAQ:ACRX) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Jul 28, 2016. Company reported revenue of $4.53M. Analysts estimated a revenue of $2.17M. Earnings per share were $-0.24. Analysts had estimated an EPS of $-0.22.
In a different note, On May 6, 2016, Seaport Global said it Upgrades its rating on AcelRx Pharmaceuticals Inc. The shares have been rated ‘Buy’ by the firm. On May 3, 2016, H.C. Wainwright said it Maintains its rating on AcelRx Pharmaceuticals Inc. In the research note, the firm Lowers the price-target to $9.00 per share. The shares have been rated ‘Buy’ by the firm.
AcelRx Pharmaceuticals Inc (ACRX) shares turned negative on Thursdays trading session with the shares closing down -0.2 points or -5.32% at a volume of 3,16,168. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $3.8. The peak price level was also seen at $3.8 while the days lowest was $3.52. Finally the shares closed at $3.56. The 52-week high of the shares is $5.88 while the 52-week low is $2.4. According to the latest information available, the market cap of the company is $161 M.
Several Insider Transactions has been reported to the SEC. On May 16, 2016, Howard B Rosen (CEO) purchased 10,206 shares at $3.26 per share price.Also, On May 12, 2016, Mark G Edwards (director) purchased 15,000 shares at $3.15 per share price.On Apr 23, 2015, Richard Afable (director) purchased 1,000 shares at $10.30 per share price, according to the Form-4 filing with the securities and exchange commission.
AcelRx Pharmaceuticals Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. The Company’s lead product candidate Zalviso is intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets delivered by the Zalviso System. The Company has three additional product candidates in clinical development: the Sufentanil Sublingual Tablet BTP Management System (ARX-02) a pain management system for the treatment of cancer patients who suffer from Breakthrough Pain (BTP); the Sufentanil/Triazolam Sublingual Tablet (ARX-03) is a single fixed-dose combination drug product designed to provide mild sedation anxiety reduction and pain relief and Sufentanil Sublingual Single-Dose Acute Pain Tablet (ARX-04) for the treatment of moderate-to-severe acute pain.